Andrew Vickers

Any suggestions as to great resources (lectures on YouTube, short didactic papers etc), to teach novice researchers about RCTs? Design, endpoints, consent, eligibility criteria, IRB etc etc any and all of it.

Is this a great argument for most statisticians to use Stata?

Guidelines for Meta-analyses and Systematic Reviews in Urology - PubMed Our guideline comprises points addressing the conduct and interpretation of systematic reviews and meta-analyses in urology. Application of the guideline would lead to a more considered interpretation of a smaller number of systematic reviews and meta-analyses, and could thus help in translating evi …

see pubmed.ncbi.nlm.nih.gov/40914655/. In brief, a random effects meta analysis requires that we estimate the random effects variance, and we can't do that if we have only a few trials. Imagine you had measured a marker on 4 patients and someone asked you what the standard deviation was.

Revman and the idea of standardizing meta-analysis was brilliant in the 1990s. That is no longer the case.

Yes, we mention that here.https://pubmed.ncbi.nlm.nih.gov/40914655/. The post was really directed at the 99% of meta-analyses that use standard software and don't even include a statistician

Email me!

COULD EVERYONE PLEASE STOP USING RANDOM EFFECTS META-ANALYSIS WHEN COMBINING 3 OR 4 TRIALS? AND COULD REVIEWERS STOP DEMANDING IT?

Great take! calibration is critical for decision making (see Ben Van Calster on this point)

​​From millionaires to Muslims, small subgroups of the population seem much larger to many Americans | YouGov When it comes to estimating the size of demographic groups, Americans rarely get it right. In two recent YouGov polls, we asked respondents to guess the percentage (ranging from 0% to 100%) of America...

today.yougov.com/politics/art...

Decision Analysis of Pelvic Lymph Node Dissection During Radical Prostatectomy | Journal of Urology Purpose:There is controversy about the decision of whether to perform a pelvic lymph node dissection (PLND) during radical prostatectomy for prostate cancer. While a recent randomized trial reported a...

www.auajournals.org/doi/10.1097/... Lymph node dissection (LND) for radical prostatectomy: controversy about RCT, complication rate. Decision analysis puts numerical estimates on benefit, harm, uncertainty. Expected utility of LND was higher vs. no PLND across broad range of scenarios.

we have shown several times that once you know PSA, PRS is non-predictive (i can send references if you like)

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study - Nature Cancer Vassy, Dornisch and colleagues developed a genomics-based prostate cancer risk model to support a randomized clinical trial of precision screening in a national healthcare system.

Yet again, PRS do not differentially distinguish aggressive from indolent cancer. & BARCODE RCT showed poor results compared to MRI etc. Yet the authors give a thumbs up to genomics in prostate cancer screening. When is the PRS fever going to break? www.nature.com/articles/s43...

Too many meta-analyses have findings equivalent to: “If you average the cost of a loaf of bread, car insurance for a year and a movie ticket, you get $752.36”

Guidelines for Reporting of Statistics for Clinical Research in Urology In an effort to improve the quality of statistics in the clinical urology literature, statisticians at European Urology, The Journal of Urology, Urology, and BJUI came together to develop a set of guidelines to address common errors of statistical ...

pmc.ncbi.nlm.nih.gov/articles/PMC...

Agree! Here is another: ratio of number of p values reported to number of patients in the study. I have seen several cases where this is > 1.

You forgot the bit: "Descriptive statistics were calculated as frequency and percentage for binary variables and mean (SD) for continuous variables, unless these were not normally distributed, in which can median and quartiles were reported"

1) A covariate that is predictive of outcome should be in the model even if unpredictive of assignment (eg matched pairs design).
2) A covariate that is not predictive of outcome should not be in the model, even if predictive of assignment.
3) The propensity score is stupid.

When discussing PSA screening policy, we often contrast two options as opportunistic vs. population-based PSA screening. Would suggest a name change to disorganized vs. organized PSA screening.

Number of papers on PubMed using the term "real world data" in 2000: 6. Number in 2025: ~5000. Number of papers for which "real world data" would be a meaningful scientific term: 0.

@amit_sud
PRS-based prostate cancer screening has worse properties than contemporary approaches: "BARCODE1 biopsied more men, diagnosed more low-grade PCs & detected fewer high-grade PCs versus Göteborg-2 and ProScreen." authors.elsevier.com/sd/article/S...

Right. Under Biden I said "I'm sorry for being white" at least five times a day (e.g. at bagel store, when I got in a cab) and often the guy at the bagel store / cab driver would say "I'm sorry for being white too". And then when Trump came in, I didn't have to say that any more. Such a timesaver!

No point in calculating, say, a p value unless you understand what it is. Or a mean vs. median unless you understand when you should report each rkbookreviews.wordpress.com/2012/05/27/w...

Evaluating Tumor Quantification in Place of Proportions in Prostate Cancer: Principles of the ProQuant Group

ProQuant collaboration: >100 urologists, radiation oncologists, pathologists, radiologists, biostatisticians, & ML experts from 34 institutions worldwide evaluating whether & how tumor quantification offers superior risk stratification to Gleason score. www.sciencedirect.com/science/arti...

Trofim Lysenko - Wikipedia

Lysenko is a bit of a bogeyman in science. But I have to say, rereading his story, hard not to draw parallels with Prasad, Makary, Bhattacharya and Hoeg. en.wikipedia.org/wiki/Trofim_...

Evaluation of performance measures in predictive artificial intelligence models to support medical decisions: overview and guidance Numerous measures have been proposed to illustrate the performance of predictive artificial intelligence (AI) models. Selecting appropriate performance measures is essential for predictive AI models i...

Our guidance regarding performance measures for medical AI models is finally out!

- Stop bashing AUROC, although it does not settle things
- Calibration and clinical utility are key
- Show risk distributions
- Classification statistics (e.g. F1) are improper

www.thelancet.com/journals/lan...

Completely agree with your analysis. With respect to AUPRC, standard recommendation is to report discrimination, calibration and clinical utility (eg decision curve). AUPRC is a from of discrimination, so i guess you could report instead of AUC. But no-one has ever explained why you should.

Working on a paper on informed decision making for PSA screening. Looking for any literature demonstrating that PSA screening is a preference sensitive decision and / or any data that these preferences can be accurately elicited in primary care. Please advise.

Machine learning has developed remarkable new ideas about how to develop prediction algorithms. But always baffled me why the field had to reinvent how to evaluate models. Here we show F score should not be used to evaluate medical prediction models link.springer.com/epdf/10.1186...

Five things you need to know about prostate cancer diagnostic tests

Five things you need to know about prostate cancer diagnostic tests www.sciencedirect.com/science/arti...

Testing Whether Cancer Screening Saves Lives: Implications for Randomized Clinical Trials of Multicancer Screening - PubMed It is not feasible to test all-cause mortality when screening for an individual cancer. However, it is feasible to test all-cause mortality for multicancer screening because cancer deaths are such a large component of deaths in general. Observational data on the effects of cancer screening are misle …

For those who complained about the recent RCT on PSA not looking at overall mortality, note that Gil Welch, the well-respected screening skeptic, concluded "It is not feasible to test all-cause mortality when screening for an individual cancer"
pubmed.ncbi.nlm.nih.gov/37639251/